Impairment of color vision is known as "Achromatopsia." This condition is multifactorial with a myriad of causes, from local at the retinal level to central at the occipital cortex level. The most common causes are inherited conditions. However, acquired achromatopsia has been acknowledged in numerous case reports and studies. Achromatopsia secondary to posterior cerebral artery (PCA) stroke is an extremely rare phenomenon and had been reported in a few case reports. In this case, we report a patient presenting with achromatopsia as the only complaint due to an infarction of the left occipital cortex.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8093119 | PMC |
| http://dx.doi.org/10.7759/cureus.14798 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cerebral achromatopsia secondary to cerebral amyloid angiopathy.
Am J Ophthalmol Case Rep
March 2025
Texas A and M School of Medicine, Bryan, TX, USA.
Prevalence of color vision deficiency in Africa: Systematic review and meta-analysis.
PLoS One
December 2024
Department of Clinical Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
Background: Color vision deficiency (CVD) cause is the difficulty distinguishing colors, which can present vocational and avocational challenges. There is a lack of data on its overall prevalence of CVD. Therefore, this systematic review and meta-analysis aim to determine the prevalence of CVD in Africa.
View Article and Find Full Text PDFSafety and Efficacy of Adeno-Associated Viral Gene Therapy in Patients With Retinal Degeneration: A Systematic Review and Meta-Analysis.
Transl Vis Sci Technol
November 2023
Neuroscience Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Purpose: This systematic review evaluates the safety and efficacy of ocular gene therapy using adeno-associated virus (AAV).
Methods: MEDLINE, Embase, Cochrane Central Register of Controlled Trials, and ClinicalTrials.gov were searched systematically for controlled or non-controlled interventional gene therapy studies using key words related to retinal diseases, gene therapy, and AAV vectors.
MFN1 augmentation prevents retinal degeneration in a Charcot-Marie-Tooth type 2A mouse model.
iScience
March 2023
Board of Governors Regenerative Medicine Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.
Charcot-Marie-Tooth disease type 2A (CMT2A), the most common inherited peripheral axonal neuropathy, is associated with more than 100 dominant mutations, including R94Q as the most abundant mutation in the Mitofusin2 (MFN2) gene. CMT2A is characterized by progressive motor and sensory loss, color-vision defects, and progressive loss of visual acuity. We used a well-established transgenic mouse model of CMT2A with R94Q mutation on MFN2 gene ( ) to investigate the functional and morphological changes in retina.
View Article and Find Full Text PDFMedical fitness to drive, emergency service vehicles and crash risk.
Ir J Med Sci
October 2023
National Office for Traffic Medicine, Royal College of Physicians of Ireland, Dublin, Ireland.
Background: Emergency service vehicle (ESV) drivers are an important part of the health, fire and police services. ESV driving is associated with increased crash risk, but little guidance exists in the literature on relevant medical conditions among drivers and their potential for adding to higher crash risks.
Aims: We undertook a narrative review to examine the role of medical and other conditions in crash risk of ESV drivers.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!